Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. GLP-1 is a hormone your gut releases after eating that signals fullness, slows gastric emptying, and supports glucose regulation. In a medical weight management program it is prescribed after doctor review and paired with nutrition, resistance training, and protein targets to protect lean mass.
Format & administration
A once-weekly subcutaneous injection using a slow titration schedule that starts low and increases only as tolerated. Your doctor sets the starting dose, the escalation pace, and the maintenance dose based on response and side effects.
Testing posture
Your doctor determines the final testing requirements for Semaglutide after reviewing your intake. The panels below are what is commonly reviewed for this therapy — they are educational guidance, not a fixed requirement.
How it works
How Semaglutide works
01By activating GLP-1 receptors in the brain and gut, semaglutide reduces appetite and food-seeking signals, slows stomach emptying so meals feel satisfying for longer, and improves glucose-dependent insulin response.
02The result is a lower spontaneous calorie intake without the constant hunger that undermines most weight loss attempts.
What has been studied
Potential applications and evidence
These areas are commonly discussed within wellness-focused protocols. They are educational statements, not medical claims or guarantees of outcome.
Doctor-directed weight management
Appetite and craving regulation
Glycemic and cardiometabolic markers
Used alongside nutrition and strength training to preserve lean mass
Doctor-guided
A personalized approach
Your doctor determines the final testing requirements for Semaglutide after reviewing your intake. The panels below are what is commonly reviewed for this therapy — they are educational guidance, not a fixed requirement.
Bloodwork status: Baseline Labs Generally Required
Commonly reviewed at baseline
A1c and fasting glucose
Comprehensive metabolic panel (CMP)
Lipid panel
Thyroid panel (TSH)
Pregnancy status where applicable
Follow-up & monitoring
Weight, blood pressure, and tolerance are reviewed at each titration step, with A1c and a metabolic panel commonly repeated at 12 weeks.
Medication review
Your doctor reviews all prescriptions, supplements, and over-the-counter medications during intake before anything is prescribed.
Format & dosing
A once-weekly subcutaneous injection using a slow titration schedule that starts low and increases only as tolerated. Your doctor sets the starting dose, the escalation pace, and the maintenance dose based on response and side effects.
Safety
What patients should know
Compounded semaglutide is not an FDA-approved product and is prepared for an individual patient pursuant to a valid prescription. Nausea, reflux, constipation, and early fullness are the most common effects and usually ease with slower titration. Not appropriate with a personal or family history of medullary thyroid carcinoma or MEN2, a history of pancreatitis, active gastroparesis, or during pregnancy or nursing.
Who may not be a candidate
Pregnancy or nursing
Active malignancy without oncology clearance
Known hypersensitivity to the preparation
Personal or family history of medullary thyroid carcinoma or MEN2
History of pancreatitis
Active gastroparesis
Regulatory status: Compounded. Evidence level: Established. Eligibility, dosing, laboratory requirements, and follow-up care are determined exclusively by a licensed doctor after review of your history.